Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 2 7Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Radiofrequency Ablation × Clear all
NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
61 enrolled 18 charts
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡